董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian K. Roberts | 男 | Director | 47 | 10.06万美元 | 未持股 | 2018-06-14 |
| John E. Timberlake | 男 | Director,Chief Executive Officer and President | 53 | 192.99万美元 | 未持股 | 2018-06-14 |
| Joe Mandato | 男 | Director | 73 | 9.06万美元 | 未持股 | 2018-06-14 |
| Luke Duster | 男 | Director | 43 | 未披露 | 未持股 | 2018-06-14 |
| Katherine D. Crothall | 女 | Director | 69 | 8.76万美元 | 未持股 | 2018-06-14 |
| Rodney Altman | 男 | Director | 55 | 9.46万美元 | 未持股 | 2018-06-14 |
| Peter Devlin | 男 | Director and Chairman | 50 | 11.22万美元 | 未持股 | 2018-06-14 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Geoffrey Jenkins | 男 | Executive Vice President, Manufacturing, Operations and Research & Development | 66 | 132.32万美元 | 未持股 | 2018-06-14 |
| Erick J. Lucera | 男 | Chief Financial Officer | 50 | 89.34万美元 | 未持股 | 2018-06-14 |
| John E. Timberlake | 男 | Director,Chief Executive Officer and President | 53 | 192.99万美元 | 未持股 | 2018-06-14 |
| Mark Conley | 男 | Vice President, Corporate Controller and Treasurer | 56 | 未披露 | 未持股 | 2018-06-14 |
| Matthew Nguyen | 男 | Chief Commercial Officer | 48 | 97.30万美元 | 未持股 | 2018-06-14 |
| Joseph Saldanha | 男 | Chief Business Officer | 53 | 未披露 | 未持股 | 2018-06-14 |
董事简历
中英对照 |  中文 |  英文- Brian K. Roberts
-
Brian K. Roberts,2015年12月以来,他是我们董事会的成员。他也曾担任Avedro, Inc(私营制药和医疗设备公司)的首席财务官(2015年1月以来),目前担任首席运营官兼首席财务官(2015年12月以来)。任职Avedro公司之前,他曾担任Insulet Corporation(医疗设备公司)的首席财务官(2009年3月以来)。他此前曾担任Jingle Networks的首席财务官(2007年8月至2009年1月),也曾担任Digitas公司的首席财务官(2001年6月至2007年7月)。他也曾担任Idiom Technologies, Inc.、the Monitor Group的财务职务,也曾担任Ernst & Young LLP的审计师。他持有Boston College的会计和财务学士学位。
Brian K. Roberts has served as a member of our board of directors since July 2016. Mr. Roberts currently serves as chief financial officer of Tarveda Therapeutics and serves as a member of the board of directors and audit chairman of ViewRay. From January 2015 to September 2016 Mr. Roberts served as the Chief Operating and Financial Officer of Avedro, a corneal cross-linking science company. From January 2009 through December 2014 he served as Chief Financial Officer for Insulet Corporation, a tubeless insulin pump technology company. From August 2007 to December 2008 Mr. Roberts served as Chief Financial Officer of Jingle Networks, a provider of advertising and technology solutions for voice and mobile business search. Mr. Roberts is currently a member of the board of directors of ViewRay, Inc. and serves as chair of its audit committee. Mr. Roberts received his Bachelor of Science in Accounting and Finance degree from Boston College. - Brian K. Roberts,2015年12月以来,他是我们董事会的成员。他也曾担任Avedro, Inc(私营制药和医疗设备公司)的首席财务官(2015年1月以来),目前担任首席运营官兼首席财务官(2015年12月以来)。任职Avedro公司之前,他曾担任Insulet Corporation(医疗设备公司)的首席财务官(2009年3月以来)。他此前曾担任Jingle Networks的首席财务官(2007年8月至2009年1月),也曾担任Digitas公司的首席财务官(2001年6月至2007年7月)。他也曾担任Idiom Technologies, Inc.、the Monitor Group的财务职务,也曾担任Ernst & Young LLP的审计师。他持有Boston College的会计和财务学士学位。
- Brian K. Roberts has served as a member of our board of directors since July 2016. Mr. Roberts currently serves as chief financial officer of Tarveda Therapeutics and serves as a member of the board of directors and audit chairman of ViewRay. From January 2015 to September 2016 Mr. Roberts served as the Chief Operating and Financial Officer of Avedro, a corneal cross-linking science company. From January 2009 through December 2014 he served as Chief Financial Officer for Insulet Corporation, a tubeless insulin pump technology company. From August 2007 to December 2008 Mr. Roberts served as Chief Financial Officer of Jingle Networks, a provider of advertising and technology solutions for voice and mobile business search. Mr. Roberts is currently a member of the board of directors of ViewRay, Inc. and serves as chair of its audit committee. Mr. Roberts received his Bachelor of Science in Accounting and Finance degree from Boston College.
- John E. Timberlake
-
John E. Timberlake,曾一直担任我们的首席执行官、总裁、我们的董事会成员(2016年2月以来),此前曾担任总裁兼首席商业官(2008年8月以来)。成为首席执行官、总裁和首席商务官之前,他曾担任我们公司的总经理(从2006年9月到2008年8月)。加入Valeritas公司之前,他曾担任Sanofi-Aventis now Sanofi公司的多种职务,并不断被提拔(从1991年到2006年),最终担任负责糖尿病营销的副总裁,在那里他负责糖尿病的特许经营,包括品牌甘精胰岛素、谷赖胰岛素、莫利阿玛尔。任职Sanofi之前,他曾担任Deloitte & Touche LLP的经理(从1986年到1991年),也曾担任注册管理会计师和注册会计师。他持有Northwest Missouri State University的会计学士学位、Purdue University的管理硕士学位,以及NEOMA Business School (f/k/a E.S.C.Rouen,位于法国)的工商管理硕士学位。
John E. Timberlake has served as our Chief Executive Officer, President and a member of our Board of Directors since February 2016 prior to which he served as President and Chief Commercial Officer since August 2008. Before becoming Chief Executive Officer and President and Chief Commercial Officer, Mr. Timberlake was a General Manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis now Sanofi, with his last role as Vice President of Diabetes Marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. Prior to Sanofi, Mr. Timberlake was a manager with Deloitte & Touche LLP, from 1986 to 1991 and was both a Certified Management Accountant and a Certified Public Accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in Management from Purdue University and an M.B.A. from NEOMA Business School (f/k/a E.S.C. Rouen) in France. - John E. Timberlake,曾一直担任我们的首席执行官、总裁、我们的董事会成员(2016年2月以来),此前曾担任总裁兼首席商业官(2008年8月以来)。成为首席执行官、总裁和首席商务官之前,他曾担任我们公司的总经理(从2006年9月到2008年8月)。加入Valeritas公司之前,他曾担任Sanofi-Aventis now Sanofi公司的多种职务,并不断被提拔(从1991年到2006年),最终担任负责糖尿病营销的副总裁,在那里他负责糖尿病的特许经营,包括品牌甘精胰岛素、谷赖胰岛素、莫利阿玛尔。任职Sanofi之前,他曾担任Deloitte & Touche LLP的经理(从1986年到1991年),也曾担任注册管理会计师和注册会计师。他持有Northwest Missouri State University的会计学士学位、Purdue University的管理硕士学位,以及NEOMA Business School (f/k/a E.S.C.Rouen,位于法国)的工商管理硕士学位。
- John E. Timberlake has served as our Chief Executive Officer, President and a member of our Board of Directors since February 2016 prior to which he served as President and Chief Commercial Officer since August 2008. Before becoming Chief Executive Officer and President and Chief Commercial Officer, Mr. Timberlake was a General Manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis now Sanofi, with his last role as Vice President of Diabetes Marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. Prior to Sanofi, Mr. Timberlake was a manager with Deloitte & Touche LLP, from 1986 to 1991 and was both a Certified Management Accountant and a Certified Public Accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in Management from Purdue University and an M.B.A. from NEOMA Business School (f/k/a E.S.C. Rouen) in France.
- Joe Mandato
-
Joe Mandato,他一直担任我们的董事(2016年12月以来)。2003年3月以来,他曾一直担任DeNovo Ventures公司(风险资本公司,专注于生命科学)的董事总经理。任职DeNovo Ventures之前,他曾担任Ioptex、Confer Software、Gynecare 、Origin Medsystems的顶级领导职务。他也曾担任AxoGen Corporation的董事会成员(2006年2月至2011年9月公司并入AxoGen, Inc.),也曾随后任职AxoGen, Inc.的董事会(直到2016年9月)。他曾担任Hansen Medical, Inc的董事会成员(从2006年8月到2012年2月)。他持有Case Western Reserve University的管理博士学位,目前任职于其监事会。他也担任the University of San Francisco的创业和管理卡洛罗西主席、Stanford University的讲师,也曾担任the Harvard University Advanced Leadership Initiative的成员。此外,他目前任职于the Embrace Global and Save、the Children organizations的董事会。
Joe Mandato, D.M. has served as a member of our board of directors since December 2016. Since March 2003 Dr. Mandato has served as a managing director of DeNovo Ventures, a venture capital firm focused on life sciences. Prior to DeNovo Ventures, Dr. Mandato held top leadership positions at Ioptex, Confer Software, Gynecare and Origin Medsystems. Dr. Mandato also served as a member of the Board of Directors of AxoGen Corporation from February 2006 until its merger with and into AxoGen, Inc. in September 2011 and then served on the Board of AxoGen, Inc. until September 2016. Dr. Mandato served as a member of the Board of Directors of Hansen Medical, Inc. from August 2006 until February 2012. Dr. Mandato received a doctorate in management from Case Western Reserve University, and now serves on its Board of Trustees. Dr. Mandato also holds the Carlo Rossi Chair in Entrepreneurship and Management at the University of San Francisco, is a Lecturer at Stanford University and has served as a Fellow in the Harvard University Advanced Leadership Initiative. Additionally, Dr. Mandato currently serves on the board of Save the Children. - Joe Mandato,他一直担任我们的董事(2016年12月以来)。2003年3月以来,他曾一直担任DeNovo Ventures公司(风险资本公司,专注于生命科学)的董事总经理。任职DeNovo Ventures之前,他曾担任Ioptex、Confer Software、Gynecare 、Origin Medsystems的顶级领导职务。他也曾担任AxoGen Corporation的董事会成员(2006年2月至2011年9月公司并入AxoGen, Inc.),也曾随后任职AxoGen, Inc.的董事会(直到2016年9月)。他曾担任Hansen Medical, Inc的董事会成员(从2006年8月到2012年2月)。他持有Case Western Reserve University的管理博士学位,目前任职于其监事会。他也担任the University of San Francisco的创业和管理卡洛罗西主席、Stanford University的讲师,也曾担任the Harvard University Advanced Leadership Initiative的成员。此外,他目前任职于the Embrace Global and Save、the Children organizations的董事会。
- Joe Mandato, D.M. has served as a member of our board of directors since December 2016. Since March 2003 Dr. Mandato has served as a managing director of DeNovo Ventures, a venture capital firm focused on life sciences. Prior to DeNovo Ventures, Dr. Mandato held top leadership positions at Ioptex, Confer Software, Gynecare and Origin Medsystems. Dr. Mandato also served as a member of the Board of Directors of AxoGen Corporation from February 2006 until its merger with and into AxoGen, Inc. in September 2011 and then served on the Board of AxoGen, Inc. until September 2016. Dr. Mandato served as a member of the Board of Directors of Hansen Medical, Inc. from August 2006 until February 2012. Dr. Mandato received a doctorate in management from Case Western Reserve University, and now serves on its Board of Trustees. Dr. Mandato also holds the Carlo Rossi Chair in Entrepreneurship and Management at the University of San Francisco, is a Lecturer at Stanford University and has served as a Fellow in the Harvard University Advanced Leadership Initiative. Additionally, Dr. Mandato currently serves on the board of Save the Children.
- Luke Duster
-
Luke Duster,2016年1月以来,他一直担任我们董事会的成员。2009年以来,他曾担任Capital Royalty Group(医疗投资公司)的董事总经理。他曾任职Harris Williams & Co。(投资公司)(2004年至2009年),在那里他曾担任副总裁。他也曾担任投资银行职务,任职于the Wallach Company(区域投资银行精品)(2000年至2002年)、the Nord Companies(医疗咨询公司)(1998年至2000年)。他获得the University of Colorado at Boulder的学士学位(以优异成绩获得),以及宾夕法尼亚大学(the University of Pennsylvania)的沃顿商学院( the Wharton School)的荣誉工商管理硕士学位。
Luke Duster has served as a member of our board of directors since January 2016. Since 2009 Mr. Duster served as managing director at Capital Royalty Group, a healthcare-focused investment firm. Mr. Duster was at Harris Williams & Co., an investment firm, from 2004 to 2009 where he served as Vice President. Mr. Duster also held investment banking roles at the Wallach Company, a regional investment banking boutique, from 2000 to 2002 and at the Nord Companies, a healthcare advisory firm, from 1998 to 2000. Mr. Duster received his B.S. summa cum laude from the University of Colorado at Boulder and an M.B.A. with honors from the Wharton School at the University of Pennsylvania. - Luke Duster,2016年1月以来,他一直担任我们董事会的成员。2009年以来,他曾担任Capital Royalty Group(医疗投资公司)的董事总经理。他曾任职Harris Williams & Co。(投资公司)(2004年至2009年),在那里他曾担任副总裁。他也曾担任投资银行职务,任职于the Wallach Company(区域投资银行精品)(2000年至2002年)、the Nord Companies(医疗咨询公司)(1998年至2000年)。他获得the University of Colorado at Boulder的学士学位(以优异成绩获得),以及宾夕法尼亚大学(the University of Pennsylvania)的沃顿商学院( the Wharton School)的荣誉工商管理硕士学位。
- Luke Duster has served as a member of our board of directors since January 2016. Since 2009 Mr. Duster served as managing director at Capital Royalty Group, a healthcare-focused investment firm. Mr. Duster was at Harris Williams & Co., an investment firm, from 2004 to 2009 where he served as Vice President. Mr. Duster also held investment banking roles at the Wallach Company, a regional investment banking boutique, from 2000 to 2002 and at the Nord Companies, a healthcare advisory firm, from 1998 to 2000. Mr. Duster received his B.S. summa cum laude from the University of Colorado at Boulder and an M.B.A. with honors from the Wharton School at the University of Pennsylvania.
- Katherine D. Crothall
-
Katherine D. Crothall,她担任Moving Image Technologies, Inc.的董事会成员(2016年10月以来)。2010年以来,她曾一直担任Aspire Bariatrics(公司致力于为肥胖患者提供安全、有效的治疗方法)的总裁、首席执行官和董事会主席。她曾担任Liberty Venture Partners(风险资本公司)的负责人(2006年至2010年11月)。她曾担任Animas Corporation(胰岛素输注泵的制造商)的创始人、总裁和首席执行官(工程创立至2006年公司被Johnson & Johnson Corporation收购)。她也曾担任另外两个医疗器械公司的创始人、总裁和首席执行官,其中包括Luxar Corporation(出售给ESC Medical)、Laakmann Electro-Optics(出售给Johnson & Johnson)。公司收购之前,她继续经营Laakmann Electro-Optics5年。她持有Pennsylvania大学的电气工程学士学位,以及Southern California大学的电气工程博士学位。她拥有20多项专利,并获得安永企业家奖(the Ernst & Young Entrepreneur of the Year Award)、大费城雷蒙德·拉弗蒂创业卓越奖(the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award)。她是Adhezion BioMedical、Xanitos, Inc的董事。她也任职于Pennsylvania大学工程和应用科学学的监事会。
Katherine D. Crothall became a Director in July 2021. Ms. Crothall has been the Chairman, Chief Executive Officer and President of Aspire Bariatrics, Inc. ("Aspire") since November 2010. Prior to Aspire, Dr. Crothall served as a Principal of Liberty Venture Partners, Inc. from 2006 to November 2010. Prior to Liberty, she founded Animas Corporation in 1996 and served as its Chairman, President, Chief Executive Officer, led its $69 million IPO in 2004, and sold it to Johnson and Johnson in 2006. From October 1988 to September 1993, Dr. Crothall served as President and Chief Executive Officer of Luxar Corporation, which she founded in 1988, sold and manufactured CO2 lasers for cosmetic, oral, surgical, dental, dermatological and surgical applications. Dr. Crothall founded Laakmann Electro Optics, which manufactured and marketed CO2 lasers and was sold to Johnson & Johnson in 1981. She was employed as an engineer at Hughes Aircraft from 1971 to 1978. She has been an Independent Director of Valeritas Holdings, Inc. since October 10, 2016. Dr. Crothall is a director of Adhezion BioMedical and a former Director of Xanitos, Inc. She served as a former Director of Othera Pharmaceuticals Inc., Intact Vascular, Inc., and Lungpacer, Inc. Dr. Crothall served as a Director of Animas Corp. since 1996 until its sale to J&J in 2006. She holds over 20 patents and is the recipient of several awards including the Ernst & Young Entrepreneur of the Year Award in 2003 and the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award in 2004. She has authored numero technical papers and has given numero papers at scientific/medical symposiums. Dr. Crothall holds a B.S. in Electrical Engineering from the University of Pennsylvania and Master of Science and a Ph.D. in Electrical Engineering from the University of Southern California. Dr. Crothall's extensive experience in public company finance and acquisition experience qualifies her to serve on board of directors. - Katherine D. Crothall,她担任Moving Image Technologies, Inc.的董事会成员(2016年10月以来)。2010年以来,她曾一直担任Aspire Bariatrics(公司致力于为肥胖患者提供安全、有效的治疗方法)的总裁、首席执行官和董事会主席。她曾担任Liberty Venture Partners(风险资本公司)的负责人(2006年至2010年11月)。她曾担任Animas Corporation(胰岛素输注泵的制造商)的创始人、总裁和首席执行官(工程创立至2006年公司被Johnson & Johnson Corporation收购)。她也曾担任另外两个医疗器械公司的创始人、总裁和首席执行官,其中包括Luxar Corporation(出售给ESC Medical)、Laakmann Electro-Optics(出售给Johnson & Johnson)。公司收购之前,她继续经营Laakmann Electro-Optics5年。她持有Pennsylvania大学的电气工程学士学位,以及Southern California大学的电气工程博士学位。她拥有20多项专利,并获得安永企业家奖(the Ernst & Young Entrepreneur of the Year Award)、大费城雷蒙德·拉弗蒂创业卓越奖(the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award)。她是Adhezion BioMedical、Xanitos, Inc的董事。她也任职于Pennsylvania大学工程和应用科学学的监事会。
- Katherine D. Crothall became a Director in July 2021. Ms. Crothall has been the Chairman, Chief Executive Officer and President of Aspire Bariatrics, Inc. ("Aspire") since November 2010. Prior to Aspire, Dr. Crothall served as a Principal of Liberty Venture Partners, Inc. from 2006 to November 2010. Prior to Liberty, she founded Animas Corporation in 1996 and served as its Chairman, President, Chief Executive Officer, led its $69 million IPO in 2004, and sold it to Johnson and Johnson in 2006. From October 1988 to September 1993, Dr. Crothall served as President and Chief Executive Officer of Luxar Corporation, which she founded in 1988, sold and manufactured CO2 lasers for cosmetic, oral, surgical, dental, dermatological and surgical applications. Dr. Crothall founded Laakmann Electro Optics, which manufactured and marketed CO2 lasers and was sold to Johnson & Johnson in 1981. She was employed as an engineer at Hughes Aircraft from 1971 to 1978. She has been an Independent Director of Valeritas Holdings, Inc. since October 10, 2016. Dr. Crothall is a director of Adhezion BioMedical and a former Director of Xanitos, Inc. She served as a former Director of Othera Pharmaceuticals Inc., Intact Vascular, Inc., and Lungpacer, Inc. Dr. Crothall served as a Director of Animas Corp. since 1996 until its sale to J&J in 2006. She holds over 20 patents and is the recipient of several awards including the Ernst & Young Entrepreneur of the Year Award in 2003 and the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award in 2004. She has authored numero technical papers and has given numero papers at scientific/medical symposiums. Dr. Crothall holds a B.S. in Electrical Engineering from the University of Pennsylvania and Master of Science and a Ph.D. in Electrical Engineering from the University of Southern California. Dr. Crothall's extensive experience in public company finance and acquisition experience qualifies her to serve on board of directors.
- Rodney Altman
-
Rodney Altman,也曾担任我们的董事会成员(2016年4月以来)。2016年6月以来,他一直担任Milestone Pharmaceuticals、Thrasos Pharmaceuticals的董事会成员,作为Business Development Bank of Canada的顾问。2011年以来,他一直担任顾问(始于2016年3月),并一直担任Spindletop Capital(私人股本和风险资本公司)的董事总经理。加入Spindletop Capital之前,他曾担任TeamHealth(美国医院人力资源公司)的区域医疗主管。他曾担任CMEA Capital, LLC(风险资本公司)的高级合伙人(2006年至2011年),在那里他曾创立并管理公司的医疗设备实践。他也曾担任其它风险基金的投资职务,其中包括Aphelion Capital, LLC、Piper Jaffray Ventures、TVM Techno Venture Management。他持有McGill University的医疗学位,以及芝加哥大学布斯商学院(the University of Chicago, Booth School of Business)的工商管理硕士学位。
Rodney Altman, M.D. has served as a member of our board of directors since April 2016. Since June 2016 Dr. Altman has been a member of the board of directors of Milestone Pharmaceuticals and Thrasos Pharmaceuticals in his capacity as an advisor to Business Development Bank of Canada. Since 2011 he has been an Advisor and beginning in March 2016 he has been a Managing Director at Spindletop Capital, a private equity and venture capital firm. Prior to joining Spindletop Capital, he was Regional Medical Director at TeamHealth, an American hospital staffing firm. Dr. Altman was a senior partner at a venture capital firm, CMEA Capital, LLC, from 2006 to 2011 where he built and managed the firm’s medical device practice. Dr. Altman has also held investing roles at other venture funds including Aphelion Capital, LLC, Piper Jaffray Ventures, and TVM Techno Venture Management. Dr. Altman received his medical degree from McGill University and an M.B.A. with honors from the University of Chicago, Booth School of Business. - Rodney Altman,也曾担任我们的董事会成员(2016年4月以来)。2016年6月以来,他一直担任Milestone Pharmaceuticals、Thrasos Pharmaceuticals的董事会成员,作为Business Development Bank of Canada的顾问。2011年以来,他一直担任顾问(始于2016年3月),并一直担任Spindletop Capital(私人股本和风险资本公司)的董事总经理。加入Spindletop Capital之前,他曾担任TeamHealth(美国医院人力资源公司)的区域医疗主管。他曾担任CMEA Capital, LLC(风险资本公司)的高级合伙人(2006年至2011年),在那里他曾创立并管理公司的医疗设备实践。他也曾担任其它风险基金的投资职务,其中包括Aphelion Capital, LLC、Piper Jaffray Ventures、TVM Techno Venture Management。他持有McGill University的医疗学位,以及芝加哥大学布斯商学院(the University of Chicago, Booth School of Business)的工商管理硕士学位。
- Rodney Altman, M.D. has served as a member of our board of directors since April 2016. Since June 2016 Dr. Altman has been a member of the board of directors of Milestone Pharmaceuticals and Thrasos Pharmaceuticals in his capacity as an advisor to Business Development Bank of Canada. Since 2011 he has been an Advisor and beginning in March 2016 he has been a Managing Director at Spindletop Capital, a private equity and venture capital firm. Prior to joining Spindletop Capital, he was Regional Medical Director at TeamHealth, an American hospital staffing firm. Dr. Altman was a senior partner at a venture capital firm, CMEA Capital, LLC, from 2006 to 2011 where he built and managed the firm’s medical device practice. Dr. Altman has also held investing roles at other venture funds including Aphelion Capital, LLC, Piper Jaffray Ventures, and TVM Techno Venture Management. Dr. Altman received his medical degree from McGill University and an M.B.A. with honors from the University of Chicago, Booth School of Business.
- Peter Devlin
-
Peter Devlin,2009年起,他担任我公司首席商务官。1998至2009年,他在Abbott Laboratories, Inc.担任多职,最近担任全球战略营销部门副总裁。1996至1998年,他担任血液检验分析系统公司i-STAT Corporation的营销经理,被Abbott Laboratories收购。1988至1996年,他还在C.R. Bard, Inc.担任多个产品管理和工程职位。他在马萨诸塞州大学(University of Massachusetts)获得机械工程学士学位。
Peter Devlin has served as a member of our board of directors since April 2016. Since September 2014 Mr. Devlin has served as a consultant for various life sciences and investment companies. From August 2009 to September 2014 Mr. Devlin was the Chief Commercial Officer at Insulet Corporation, a tubeless insulin pump technology company. Mr. Devlin held several leadership roles at Abbott Laboratories, Inc. From February 2008 to July 2009 he served as Divisional Vice President of Abbott’s Global Strategic Marketing in the diabetes care unit, prior to which he served as General Manager, Hospital & Government in the diabetes care unit from December 2006 to February 2008 and prior to which he served as Director of Abbott’s Canadian diabetes unit from September 2003 to December 2006. Mr. Devlin received his Bachelor of Science degree from the University of Massachusetts. - Peter Devlin,2009年起,他担任我公司首席商务官。1998至2009年,他在Abbott Laboratories, Inc.担任多职,最近担任全球战略营销部门副总裁。1996至1998年,他担任血液检验分析系统公司i-STAT Corporation的营销经理,被Abbott Laboratories收购。1988至1996年,他还在C.R. Bard, Inc.担任多个产品管理和工程职位。他在马萨诸塞州大学(University of Massachusetts)获得机械工程学士学位。
- Peter Devlin has served as a member of our board of directors since April 2016. Since September 2014 Mr. Devlin has served as a consultant for various life sciences and investment companies. From August 2009 to September 2014 Mr. Devlin was the Chief Commercial Officer at Insulet Corporation, a tubeless insulin pump technology company. Mr. Devlin held several leadership roles at Abbott Laboratories, Inc. From February 2008 to July 2009 he served as Divisional Vice President of Abbott’s Global Strategic Marketing in the diabetes care unit, prior to which he served as General Manager, Hospital & Government in the diabetes care unit from December 2006 to February 2008 and prior to which he served as Director of Abbott’s Canadian diabetes unit from September 2003 to December 2006. Mr. Devlin received his Bachelor of Science degree from the University of Massachusetts.
高管简历
中英对照 |  中文 |  英文- Geoffrey Jenkins
Geoffrey Jenkins自2009年4月加入Valeritas起,Geoffrey Jenkins担任公司制造、运营和研发的执行副总裁。加入Valeritas之前,2005年至2009年Jenkins先生是Inverness Medical(一家医疗保健科技公司)的全球运营副总裁。2000年至2005年,他是UV-Solutions, LLC(一家医疗技术公司)的总裁和创始合伙人;1997年至1999年,他担任MDI Instruments, Inc.(一家医疗保健技术公司)的首席运营官。1991年至1997年,Jenkins先生也是MediSense, Inc.的运营副总裁。在成为公司运营副总裁之前,1984年至1991年他在MediSense担任各种运营和工程管理岗位。Jenkins先生获得Clarkson University文学士学位和理学士学位。
Geoffrey Jenkins, Mr. Jenkins has served as our Executive Vice President, Manufacturing, Operations and Research & Development since he joined Valeritas in April 2009. Mr. Jenkins was Vice President of Worldwide Operations for Inverness Medical, a healthcare technology company, from 2005 to 2009. From 2000 to 2005 he was President and Founding Partner of UV-Solutions, LLC, a healthcare technology company, and from 1997 to 1999 he was Chief Operating Officer of MDI Instruments, Inc., a healthcare technology company. Mr. Jenkins was also Corporate Vice President of Operations of MediSense, Inc. from 1991 to 1997. Prior to becoming Corporate Vice President of Operations, he held various other positions in Operations and Engineering Management with MediSense from 1984 to 1991. Mr. Jenkins earned a B.A. and a B.S. from Clarkson University.- Geoffrey Jenkins自2009年4月加入Valeritas起,Geoffrey Jenkins担任公司制造、运营和研发的执行副总裁。加入Valeritas之前,2005年至2009年Jenkins先生是Inverness Medical(一家医疗保健科技公司)的全球运营副总裁。2000年至2005年,他是UV-Solutions, LLC(一家医疗技术公司)的总裁和创始合伙人;1997年至1999年,他担任MDI Instruments, Inc.(一家医疗保健技术公司)的首席运营官。1991年至1997年,Jenkins先生也是MediSense, Inc.的运营副总裁。在成为公司运营副总裁之前,1984年至1991年他在MediSense担任各种运营和工程管理岗位。Jenkins先生获得Clarkson University文学士学位和理学士学位。
- Geoffrey Jenkins, Mr. Jenkins has served as our Executive Vice President, Manufacturing, Operations and Research & Development since he joined Valeritas in April 2009. Mr. Jenkins was Vice President of Worldwide Operations for Inverness Medical, a healthcare technology company, from 2005 to 2009. From 2000 to 2005 he was President and Founding Partner of UV-Solutions, LLC, a healthcare technology company, and from 1997 to 1999 he was Chief Operating Officer of MDI Instruments, Inc., a healthcare technology company. Mr. Jenkins was also Corporate Vice President of Operations of MediSense, Inc. from 1991 to 1997. Prior to becoming Corporate Vice President of Operations, he held various other positions in Operations and Engineering Management with MediSense from 1984 to 1991. Mr. Jenkins earned a B.A. and a B.S. from Clarkson University.
- Erick J. Lucera
Erick J. Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology(Nasdaq:AVEO)的首席财务官,AVEO Oncology是一家在纳斯达克上市的生物制药公司,2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年,Lucera先生担任Valeritas Holdings, Inc.(一家在美国纳斯达克上市的商业公司,开发糖尿病新技术)的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年,他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间,他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易,帮助扩大了公司的产品线。在担任医疗保健公司高管之前,Lucera先生在投资管理领域度过了超过15年,曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起,他担任Bone Biologics的董事会成员,Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
Erick J. Lucera joined Board of Directors in Augt 2017. He has served as the Chief Financial Officer of Dyne Therapeutics, Inc. (Nasdaq: DYN), a Nasdaq listed biotechnology company foced on developing targeted therapies for people living with genetically driven neuromcular disease, since March 31, 2025. He previoly served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc. (Nasdaq: EDIT), a Nasdaq listed clinical stage genome editing company, from May 2023 to March 2025. He was the Chief Financial Officer of AVEO Oncology (Nasdaq: AVEO), a Nasdaq traded biopharmaceutical company foced on targeted medicines for oncology and other unmet medical needs, from 2020 to 2023, when it was acquired by LG Chem, and was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company's product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors of SAB Biopharmapeutics, Inc., a Nasdaq traded clinical stage biopharmaceutical company, since April 2023. He holds a CPH from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.- Erick J. Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology(Nasdaq:AVEO)的首席财务官,AVEO Oncology是一家在纳斯达克上市的生物制药公司,2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年,Lucera先生担任Valeritas Holdings, Inc.(一家在美国纳斯达克上市的商业公司,开发糖尿病新技术)的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年,他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间,他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易,帮助扩大了公司的产品线。在担任医疗保健公司高管之前,Lucera先生在投资管理领域度过了超过15年,曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起,他担任Bone Biologics的董事会成员,Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
- Erick J. Lucera joined Board of Directors in Augt 2017. He has served as the Chief Financial Officer of Dyne Therapeutics, Inc. (Nasdaq: DYN), a Nasdaq listed biotechnology company foced on developing targeted therapies for people living with genetically driven neuromcular disease, since March 31, 2025. He previoly served as Executive Vice President and Chief Financial Officer of Editas Medicine, Inc. (Nasdaq: EDIT), a Nasdaq listed clinical stage genome editing company, from May 2023 to March 2025. He was the Chief Financial Officer of AVEO Oncology (Nasdaq: AVEO), a Nasdaq traded biopharmaceutical company foced on targeted medicines for oncology and other unmet medical needs, from 2020 to 2023, when it was acquired by LG Chem, and was the Chief Financial Officer of Valeritas Holdings, Inc., a U.S. Nasdaq traded commercial stage company developing new technology for diabetes, from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio from 2015 to 2016. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company's product pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He has served on the board of directors of SAB Biopharmapeutics, Inc., a Nasdaq traded clinical stage biopharmaceutical company, since April 2023. He holds a CPH from Harvard University, an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.
- John E. Timberlake
John E. Timberlake,曾一直担任我们的首席执行官、总裁、我们的董事会成员(2016年2月以来),此前曾担任总裁兼首席商业官(2008年8月以来)。成为首席执行官、总裁和首席商务官之前,他曾担任我们公司的总经理(从2006年9月到2008年8月)。加入Valeritas公司之前,他曾担任Sanofi-Aventis now Sanofi公司的多种职务,并不断被提拔(从1991年到2006年),最终担任负责糖尿病营销的副总裁,在那里他负责糖尿病的特许经营,包括品牌甘精胰岛素、谷赖胰岛素、莫利阿玛尔。任职Sanofi之前,他曾担任Deloitte & Touche LLP的经理(从1986年到1991年),也曾担任注册管理会计师和注册会计师。他持有Northwest Missouri State University的会计学士学位、Purdue University的管理硕士学位,以及NEOMA Business School (f/k/a E.S.C.Rouen,位于法国)的工商管理硕士学位。
John E. Timberlake has served as our Chief Executive Officer, President and a member of our Board of Directors since February 2016 prior to which he served as President and Chief Commercial Officer since August 2008. Before becoming Chief Executive Officer and President and Chief Commercial Officer, Mr. Timberlake was a General Manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis now Sanofi, with his last role as Vice President of Diabetes Marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. Prior to Sanofi, Mr. Timberlake was a manager with Deloitte & Touche LLP, from 1986 to 1991 and was both a Certified Management Accountant and a Certified Public Accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in Management from Purdue University and an M.B.A. from NEOMA Business School (f/k/a E.S.C. Rouen) in France.- John E. Timberlake,曾一直担任我们的首席执行官、总裁、我们的董事会成员(2016年2月以来),此前曾担任总裁兼首席商业官(2008年8月以来)。成为首席执行官、总裁和首席商务官之前,他曾担任我们公司的总经理(从2006年9月到2008年8月)。加入Valeritas公司之前,他曾担任Sanofi-Aventis now Sanofi公司的多种职务,并不断被提拔(从1991年到2006年),最终担任负责糖尿病营销的副总裁,在那里他负责糖尿病的特许经营,包括品牌甘精胰岛素、谷赖胰岛素、莫利阿玛尔。任职Sanofi之前,他曾担任Deloitte & Touche LLP的经理(从1986年到1991年),也曾担任注册管理会计师和注册会计师。他持有Northwest Missouri State University的会计学士学位、Purdue University的管理硕士学位,以及NEOMA Business School (f/k/a E.S.C.Rouen,位于法国)的工商管理硕士学位。
- John E. Timberlake has served as our Chief Executive Officer, President and a member of our Board of Directors since February 2016 prior to which he served as President and Chief Commercial Officer since August 2008. Before becoming Chief Executive Officer and President and Chief Commercial Officer, Mr. Timberlake was a General Manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis now Sanofi, with his last role as Vice President of Diabetes Marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. Prior to Sanofi, Mr. Timberlake was a manager with Deloitte & Touche LLP, from 1986 to 1991 and was both a Certified Management Accountant and a Certified Public Accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in Management from Purdue University and an M.B.A. from NEOMA Business School (f/k/a E.S.C. Rouen) in France.
- Mark Conley
Mark Conley,康利先生自2016年2月以来一直担任我们的Vice President,公司财务总监兼财务主管,在此之前,他自2012年8月加入Valeritas以来一直担任我们的财务规划与分析总监。Conley先生从2007年到2012年担任Thermo Fisher Scientific辐射仪器业务的全球财务总监。此外,他曾在Iron Mountain,Inc.担任Vice President,2005年至2007年6月担任财务规划和分析,1998年至2004年担任部门财务总监,1996年至1998年担任Holtrachem Group的首席财务官和财务总监,1991年至1996年担任Haemonetics Corporation的运营总监等一系列财务领导职务。Conley先生在俄克拉荷马州立大学(Oklahoma State University)获得会计学学士学位,在布赖恩特学院(Bryant College)获得工商管理硕士学位,并且是一名注册会计师。
Mark Conley, Mr. Conley has served as our Vice President, Corporate Controller and Treasurer since February 2016 prior to which he served as our Director of Financial Planning & Analysis since joining Valeritas in August 2012. Mr. Conley was Global Finance Director of the radiation instrumentation business at Thermo Fisher Scientific from 2007 to 2012. In addition, he served at Iron Mountain, Inc. as Vice President, Financial Planning & Analysis from 2005 to June 2007 and Division Controller from 1998 to 2004 as Chief Financial Officer and Controller at HoltraChem Group from 1996 to 1998 and in successive financial leadership roles including Operations Controller at Haemonetics Corporation from 1991 to 1996. Mr. Conley earned a B.S. in Accounting from Oklahoma State University, an M.B.A. from Bryant College, and is a Certified Public Accountant.- Mark Conley,康利先生自2016年2月以来一直担任我们的Vice President,公司财务总监兼财务主管,在此之前,他自2012年8月加入Valeritas以来一直担任我们的财务规划与分析总监。Conley先生从2007年到2012年担任Thermo Fisher Scientific辐射仪器业务的全球财务总监。此外,他曾在Iron Mountain,Inc.担任Vice President,2005年至2007年6月担任财务规划和分析,1998年至2004年担任部门财务总监,1996年至1998年担任Holtrachem Group的首席财务官和财务总监,1991年至1996年担任Haemonetics Corporation的运营总监等一系列财务领导职务。Conley先生在俄克拉荷马州立大学(Oklahoma State University)获得会计学学士学位,在布赖恩特学院(Bryant College)获得工商管理硕士学位,并且是一名注册会计师。
- Mark Conley, Mr. Conley has served as our Vice President, Corporate Controller and Treasurer since February 2016 prior to which he served as our Director of Financial Planning & Analysis since joining Valeritas in August 2012. Mr. Conley was Global Finance Director of the radiation instrumentation business at Thermo Fisher Scientific from 2007 to 2012. In addition, he served at Iron Mountain, Inc. as Vice President, Financial Planning & Analysis from 2005 to June 2007 and Division Controller from 1998 to 2004 as Chief Financial Officer and Controller at HoltraChem Group from 1996 to 1998 and in successive financial leadership roles including Operations Controller at Haemonetics Corporation from 1991 to 1996. Mr. Conley earned a B.S. in Accounting from Oklahoma State University, an M.B.A. from Bryant College, and is a Certified Public Accountant.
- Matthew Nguyen
Matthew Nguyen,2016年12月以来,他一直担任我们的首席商业官。他曾担任我们的高级商业副总裁(2016年2月至2016年12月),以及我们的综合医疗管理副总裁(2006年9月加入Valeritas公司以来)。他曾担任Janssen, LP(从属于Johnson & Johnson)的新业务发展主管(2005年至2006年)。他曾担任Sanofi公司的新陈代谢的卫生经济研究、新产品营销主管,以及中枢神经系统业务单位的分析和商业效益主管。他持有the Philadelphia College of Pharmacy and Science的制药学士学位和制药博士学位。他还完成了Thomas Jefferson University Hospital、 Janssen Pharmaceutical, Inc的卫生经济学和结果研究,并获得Rutgers University(位于新泽西州)的工商管理硕士学位。
Matthew Nguyen, Mr. Nguyen has served as our Chief Commercial Officer since December 2016. Mr. Nguyen served as our Sr. Vice President, Commercial from February 2016 to December 2016 and as our Vice President for Integrated Healthcare Management since joining Valeritas in September 2006. Mr. Nguyen was a New Business Development Director for Janssen, LP, a division of Johnson & Johnson, from 2005 to 2006. He served as head of health economics research for metabolism, new product marketing, and head of analytics and commercial effectiveness for the CNS business unit at Sanofi from 2000 to 2005. Mr. Nguyen earned a B.S. in Pharmacy and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He also completed a Fellowship in Health Economics and Outcomes Research in conjunction with Thomas Jefferson University Hospital and Janssen Pharmaceutical, Inc. and earned an M.B.A. from Rutgers University in New Jersey.- Matthew Nguyen,2016年12月以来,他一直担任我们的首席商业官。他曾担任我们的高级商业副总裁(2016年2月至2016年12月),以及我们的综合医疗管理副总裁(2006年9月加入Valeritas公司以来)。他曾担任Janssen, LP(从属于Johnson & Johnson)的新业务发展主管(2005年至2006年)。他曾担任Sanofi公司的新陈代谢的卫生经济研究、新产品营销主管,以及中枢神经系统业务单位的分析和商业效益主管。他持有the Philadelphia College of Pharmacy and Science的制药学士学位和制药博士学位。他还完成了Thomas Jefferson University Hospital、 Janssen Pharmaceutical, Inc的卫生经济学和结果研究,并获得Rutgers University(位于新泽西州)的工商管理硕士学位。
- Matthew Nguyen, Mr. Nguyen has served as our Chief Commercial Officer since December 2016. Mr. Nguyen served as our Sr. Vice President, Commercial from February 2016 to December 2016 and as our Vice President for Integrated Healthcare Management since joining Valeritas in September 2006. Mr. Nguyen was a New Business Development Director for Janssen, LP, a division of Johnson & Johnson, from 2005 to 2006. He served as head of health economics research for metabolism, new product marketing, and head of analytics and commercial effectiveness for the CNS business unit at Sanofi from 2000 to 2005. Mr. Nguyen earned a B.S. in Pharmacy and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He also completed a Fellowship in Health Economics and Outcomes Research in conjunction with Thomas Jefferson University Hospital and Janssen Pharmaceutical, Inc. and earned an M.B.A. from Rutgers University in New Jersey.
- Joseph Saldanha
Joseph Saldanha,Saldanha先生自2018年1月起担任我们的首席商务官。2016年4月至2017年7月,Saldanha先生担任Mannkind Corporation Vice President,营销和业务开发。Saldanha从2012年1月到2015年5月担任Gulphar Pharmaceutical Industries糖尿病总经理。从2001年到2008年,Saldanha先生还曾在Aventis‑;Pfizer合伙公司为Exubera和赛诺菲及其前身工作,在美国推出Actonel治疗骨质疏松症,并在巴黎的国际市场为Lantus工作。从2012年到2015年,Saldanha先生还在阿拉伯联合酋长国担任一般管理职位,负责胰岛素原料药,糖尿病口服制剂和注射剂,以及Dexcom CGM在东部市场的分销。Saldanha先生在费城德雷克塞尔大学(Drexel University)获得理学学士学位,并在宾夕法尼亚大学(University of Pennsylvania)获得理学硕士学位。
Joseph Saldanha, Mr. Saldanha has served as our Chief Business Officer since January 2018. From April 2016 to July 2017 Mr. Saldanha served as Vice President, Marketing and Business Development of MannKind Corporation. From January 2012 to May 2015 Mr. Saldanha was the General Manager, JULPHAR Diabetes for Gulf Pharmaceutical Industries. Mr. Saldanha has also worked on the Aventis‑Pfizer partnership for Exubera and for Sanofi and its predecessors from 2001 to 2008 launching Actonel for osteoporosis in the U.S., and for Lantus in international markets from Paris. Mr. Saldanha also worked in the United Arab Emirates in a general management role with responsibility for insulin API, diabetes orals and injectables, and distribution of Dexcom CGM for the Middle‑Eastern markets from 2012 to 2015. Mr. Saldanha earned a Bachelor of Science degree from Drexel University and a Master of Science degree from the University of Pennsylvania, both in Philadelphia.- Joseph Saldanha,Saldanha先生自2018年1月起担任我们的首席商务官。2016年4月至2017年7月,Saldanha先生担任Mannkind Corporation Vice President,营销和业务开发。Saldanha从2012年1月到2015年5月担任Gulphar Pharmaceutical Industries糖尿病总经理。从2001年到2008年,Saldanha先生还曾在Aventis‑;Pfizer合伙公司为Exubera和赛诺菲及其前身工作,在美国推出Actonel治疗骨质疏松症,并在巴黎的国际市场为Lantus工作。从2012年到2015年,Saldanha先生还在阿拉伯联合酋长国担任一般管理职位,负责胰岛素原料药,糖尿病口服制剂和注射剂,以及Dexcom CGM在东部市场的分销。Saldanha先生在费城德雷克塞尔大学(Drexel University)获得理学学士学位,并在宾夕法尼亚大学(University of Pennsylvania)获得理学硕士学位。
- Joseph Saldanha, Mr. Saldanha has served as our Chief Business Officer since January 2018. From April 2016 to July 2017 Mr. Saldanha served as Vice President, Marketing and Business Development of MannKind Corporation. From January 2012 to May 2015 Mr. Saldanha was the General Manager, JULPHAR Diabetes for Gulf Pharmaceutical Industries. Mr. Saldanha has also worked on the Aventis‑Pfizer partnership for Exubera and for Sanofi and its predecessors from 2001 to 2008 launching Actonel for osteoporosis in the U.S., and for Lantus in international markets from Paris. Mr. Saldanha also worked in the United Arab Emirates in a general management role with responsibility for insulin API, diabetes orals and injectables, and distribution of Dexcom CGM for the Middle‑Eastern markets from 2012 to 2015. Mr. Saldanha earned a Bachelor of Science degree from Drexel University and a Master of Science degree from the University of Pennsylvania, both in Philadelphia.